Restricted availability under an FDA-mandated drug safety program has limited the reach of CAR-T cell therapies for certain ...

The Breyanzi REMS program and the Abecma REMS program were established due to the risk of cytokine release syndrome and neurologic toxicities.

Bristol Myers Squibb (BMS) received U.S. Food and Drug Administration (FDA) approval for label updates for its CAR T cell ...

Abecma Market Research Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts 2019-2024, 2024-2029F, 2034F ...

Abecma’s review was delayed after the FDA rejected a first filing in May last year, but it’s hoped that the drug could be a significant step forward in the treatment of this incurable condition.

Label updates have been approved by the FDA for the CAR T-cell therapies Breyanzi and Abecma in large B cell lymphoma and ...

Major players operating in the abecma market are Bristol-Myers Squibb. North America was the largest region in the abecma market in 2024. The regions covered in abecma report are Asia-Pacific, Western ...

FDA Removes Risk Evaluation and Mitigation Strategy (REMS) for chimeric antigen receptor (CAR) T-cell Therapies: Updated labels for Breyanzi and Abecma eliminate REMS requirements, reflecting improved ...

The FDA said risks linked to CAR-T cell therapies can be effectively communicated through existing labeling, including boxed ...

Bristol Myers Squibb has announced that the FDA has given approval to label updates for Breyanzi and Abecma to treat multiple myeloma.